Unipharma.ch

FDA Approves Ofatumumab (Arzerra) for Patients With CLL Refractory to Fludarabine and Alemtuzumab

RoActemra Receives Positive Opinion in Europe for the Treatment of Rheumatoid ArthritisFirst-in-class therapy represents a novel approach to treat patients with moderate to severe rheumatoid arthritis.

LITAK^® is approved for recurrent or refractory follicular and diffuse non-Hodgkin's lymphoma, recurrent or refractory chronic lymphocytic leukemia and recurrent or refractory lymphoplasmacytic lymphoma (Waldenström's macroglobulinemia) in Switzerland (country of origin) since 2000.

Bayer will start marketing the new oral, once-daily anticoagulant very soon / First-in-class product to demonstrate superior efficacy to current standard of care

A partire dal 01 novembre 2008 Unipharma SA distribuirà in esclusiva in Italia il prodotto:

PRILOCAINE HYPERBAR SINTETICA  2%  10 fiale  5 ml

The system for online consultation of drugs that Unipharma offers on the marketwas activated. You can request the activation of an account to access the restricted area.

GlaxoSmithKline announced today that the U.S. Food and Drug Administration (FDA) has approved Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine], the first combination vaccine to offer protection against diphtheria, tetanus, pertussis and polio diseases in one shot.